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Abstract: Cytochromes P450 (CYP450s) promote the biosynthesis of steroid hormones with
major impact on the onset of diseases such as breast and prostate cancers. By merging distinct
functions into the same catalytic scaffold, steroidogenic CYP450s enhance complex chemical
transformations with extreme efficiency and selectivity. Mammalian CYP450s and their redox
partners are membrane-anchored proteins, dynamically associating to form functional machineries.
Mounting evidence signifies that environmental factors are strictly intertwined with CYP450s catalysis.
Atomic-level simulations have the potential to provide insights into the catalytic mechanism of
steroidogenic CYP450s and on its regulation by environmental factors, furnishing information
often inaccessible to experimental means. In this review, after an introduction of computational
methods commonly employed to tackle these systems, we report the current knowledge on three
steroidogenic CYP450s—CYP11A1, CYP17A1, and CYP19A1—endowed with multiple catalytic
functions and critically involved in cancer onset. In particular, besides discussing their catalytic
mechanisms, we highlight how the membrane environment contributes to (i) regulate ligand
channeling through these enzymes, (ii) modulate their interactions with specific protein partners,
(iii) mediate post-transcriptional regulation induced by phosphorylation. The results presented set
the basis for developing novel therapeutic strategies aimed at fighting diseases originating from
steroid metabolism dysfunction.
Keywords: Cytochrome P450; phosphorylation; membrane modulation; molecular dynamics;
QM/MM; breast cancer; prostate cancer
1. Introduction
Cytochromes P450 (CYP450s) catalyze a variety of reactions over a broad range of substrates,
being among the most versatile enzymes in Nature. These promote the biotransformation of a wide
spectrum of xenobiotic and endogenous compounds [1], in addition to the biosynthesis of steroid
hormones and the conversion of polyunsaturated fatty acids. Hence, CYP450s play a regulatory role as
the basis of homeostasis and development, and promote the metabolism of carcinogenic species and of
many marketed drugs [2]. The nomenclature employed to categorize this complex and growing family
of enzymes is based on the name of the genes, which uses the italicized prefix “CYP” for humans,
followed by an Arabic number to denote the family, a letter to designate the subfamily, and, finally,
another number referring to the specific cytochrome. The encoded proteins are identified by the same
name of the gene without the use of italics (e.g., the CYP19A1 genes encodes for CYP19A1 protein) [3].
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In humans six CYP450s participate in steroidogenesis, a fundamental metabolic pathway that
leads to the formation of biologically active steroid hormones, starting from cholesterol (see Figure 1) [4].
These are divided in type I and II enzymes carrying out their action in the mitochondria and in the
endoplasmic reticulum (ER), respectively. An altered regulation of steroidogenesis induces the onset of
several pathologies, such as polycystic ovary syndrome, hypertension, and of distinct cancer types (i.e.,
breast and prostate cancers). Hence, understanding the mechanism of steroidogenesis has innumerable
biological and pharmacological implications and is rooted into unraveling their biochemistry as well as
the multiple regulatory mechanisms finely tuning steroid production. CYP450s are typically classified as
monooxygenases, which catalyze the hydroxylation of organic molecules, requiring molecular oxygen,
protons, and electrons supplied from water molecules and specific protein partners, respectively. It is now
commonly accepted that the hydroxylation reaction is mediated by Compound I (Cpd I) via an oxygen
rebound mechanism [5,6]. However, besides the canonical mono-oxygenation, CYP450s can promote
a variety of distinct chemical reactions, including deformylation, desaturation, and C–C coupling [7,8].
While, only two enzymes (CYP11B1 and CYP21A2, involved in the synthesis of both glucocorticoids
and mineralocorticoids) are endowed with exclusive hydroxylase activity, the others are characterized by
intricate catalytic mechanisms, in which different functions are merged within the same catalytic scaffold,
adding fascinating complexity to their catalytic mechanism. These are: (i) CYP11A1, also called cholesterol
side-chain cleavage enzyme (P450scc), the first enzyme of steroid biosynthesis; (ii) CYP19A1, commonly
called Aromatase (AR), which catalyzes estrogen biosynthesis and (iii) CYP17A1, which remarkably joins
a 17α-hydroxylase with 17,20-lyase function [4].
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Figure 1. Schematic picture of steroidogenesis. Mitochondrial and microsomal Cytochromes P450 (CYP450s)
are highlighted in red and blue, respectively. Two dehydrogenases, 3β and 17β, are highlighted in black.
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All mammalian CYP450s are attached and partially immersed to ER or mitochondrial membranes
via an N-terminal helix spanning the lipidic bilayer [9]. Their membrane-bound nature makes it
challenging to obtain crystal structures [10]. These latter represent the main sources of structural
information needed to disclose CYP450s’ function.
The electrons are key ingredients of the chemical reactions catalyzed by CYP450s. For microsomal
CYP450s these are provided by the cytochrome P450 reductase (CPR), and Cytochrome b5 (CYb5),
membrane-attached proteins located in the ER, whereas in the mitochondrial membrane they
are supplied by the ferredoxin system (Adrenodoxin (Adx), a Fe2S2 containing ferredoxin, and
Adrenodoxin Reductase (AdR)). Mounting evidence has indicated how the function of CYP450s
machinery is intrinsically connected with their membrane bound nature. Indeed, protein-lipid
interactions modulate CYP450s flooding and diffusion on the top of membranes, finely regulating
their catalysis as well as substrate selectivity, and interaction with essential protein partners [11].
This review focuses in particular on CYP19A1, CYP17A1, and CYP11A1 as a proxy of steroidogenic
CYP450s. These enzymes have been selected for their intricate catalytic mechanisms merging different
functions, their crucial involvement in severe pathologies (cancer, pre-eclampsia etc), and for their
relevance as pharmaceutical targets. Due to its captivating complexity, unraveling the mechanism
of the steroidogenic machinery requires the complementary use of biochemical and biophysical
experimental techniques along with atomic-level simulations. This review is mostly focused on the
achievements attained in understanding the different facets of CYP450s’ mechanism by means of
all-atom simulations. Hence, after a brief introduction on computational methods employed to tackle
these systems, we discuss: (i) the general CYP450 catalytic mechanism, highlighting its specificity
in steroidogenesis; (ii) the role of biological membranes in affecting substrate/drug channeling and
their substrate selectivity by sculpting distinct access/egress channels to the active site, and, finally,
(iii) a common post-transcriptional regulation mechanism of CYP450s induced by phosphorylation.
Unraveling the inner-working mechanism of this intricate and utmost important machinery has
broad biological and pharmacological implications to tackle disorders linked to steroid metabolism
dysfunction, setting the basis for novel inhibitory strategies against cancer (breast and prostate) disease.
2. Computational Methods to Dissect the Mechanism of CYP450s
2.1. Force Field Based Molecular Dynamics (MD)
The intricate chemical and regulatory mechanisms underlining CYP450s’ functions requires the
use of several complementary biochemical and biophysical techniques to be disentangled. Among
the available tools, computer simulations have the potential to tackle such mechanisms reaching a
temporal and spatial resolution inaccessible, yet complementary, to experimental methods. In this
respect, molecular dynamics (MD) simulations have often been used to study CYP450s. This method
allows the dynamic evolution of a system to be followed at near-physiological conditions, while its
thermodynamic properties are calculated from averages over sufficiently long trajectories [12]. By
calculating the forces acting on a system’s particles, these can be propagated via a suitable equation
of motions. In classical MD the interactions between atoms are described with empirical force fields
(FFs). In these, the potential energy is expressed as the sum of bonded contributions (bonds, angles,
dihedrals, improper dihedrals) and nonbonded terms (Coulomb potential to model electrostatics
and Lennard–Jones to describe atom–atom attraction/repulsion and dispersion interactions). Besides
providing information on the dynamic evolution of the system, classical MD allows the interaction
of biomolecules to be characterized with the surrounding environment at the atomic-scale and is
routinely employed to study large biomolecular machineries comprising up to millions of atoms [13],
and reaching timescales of the order of 10–100 of microseconds [14].
For CYP450s extensive MD simulations have contributed to unravel the model and the principles
driving the interaction between these proteins and their associated membranes [15–18], predicting how
CYP450s float on the ER or mitochondrial membranes, assessing their orientation with respect to the
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membrane plane, and their immersion inside the lipidic bilayer, as well as assessing the influence of the
lipid type on these properties, on the slow functional motion of the enzymes, and on ligand-channeling
to the active site from the protein surface [17,19,20]. In this latter case, the typical simulation time-scale
of classical MD is, however, not sufficient to identify possible ligand routes, and to identify the most
viable channels by calculating the relative free energy profiles for ligand passage through the protein.
Hence, methods capable of estimating thermodynamic quantities (free energy, entropy, and enthalpy)
and kinetic parameters (free energy barriers) rigorously from MD simulations have been developed.
These allow predicting equilibrium observables from non-equilibrium “biased” MD simulations.
Random expulsion molecular dynamics (RAMD) simulations have been often applied to sample
ligands travelling along CYP450 channels [16]. By applying randomly oriented forces to the ligand
atoms, one can quickly identify possible escape routes which from the active site reach the protein
surface. By repeating these ligand dissociation events several times, it is possible to identify the most
likely dissociation paths at statistical level. Alternatively, Steered MD (SMD) can be employed to induce
the dissociation of a ligand by applying an external force. This is usually done along predefined routes
(such as those identified by RAMD) [17,21]. Nevertheless, obtaining a convergent free energy profile
by using the SMD simulations and the Jarzinski’s equality is challenging [21,22]. Hence, information
on free energy profiles can be obtained by complementary methods, able to force the exploration along
a predefined reaction coordinate. In any MD simulation, the exploration of the phase space is limited
by Boltzmann statistics, so that at equilibrium the system will sample only a limited portion of the
conformational space. In Umbrella Sampling (US) this probability is modified by adding a bias to
the potential in order to force the exploration of important regions, which would be rarely accessible
by Boltzmann statistics. This enhanced non-Boltzmann sampling is forced around specific values
of the selected reaction coordinate. Thus, in order to get a reliable estimate of the potential of mean
force, one needs to run several simulations centered on distinct points of the reaction coordinate, and
then reconstruct the unbiased potential of mean force by the Weighted Histogram Analysis Method
(WHAM) [12,23].
Conversely, metadynamics represents an efficient approach to enhance the sampling of
conformational space, without a priory guess of the reaction coordinate. By means of a history-dependent
biasing potential, the system is encouraged to visit new (Boltzmann disfavored) states, which allow it
to evolve toward different stable/metastable states, and the (negative of the) biasing potential provides
an estimate of the underlying free energy surface. In the original implementation, the method relies
on the identification of two reaction coordinates (named collective variables). Several variants of this
original scheme [24] have been introduced to allow faster exploration and convergence of the free
energy [25,26].
2.2. Mixed Quantum-Classical (QM/MM) Static or Dynamics Simulations
Relying on a predefined potential energy surface, FFs cannot be used to investigate processes
in which a change of the electronic structure occurs (i.e., chemical reactions [27–29], polarization,
and charge transfer effects [30], as well as rearrangements in the sphere of the transition metals [31]).
In these cases, a quantum mechanical (QM)-based approach is mandatory. Despite the significant
improvement of computational software, algorithms, and computer architectures, QM calculations
are still too expensive for tackling biomolecules in their physiological environment. Therefore, QM
studies of enzymatic reactions are typically performed with a mixed Quantum Mechanics–Molecular
Mechanics approach (QM/MM) [32]. In this multiscale method, the reaction site is treated by using
the QM level of theory, while the rest of the system is treated by using Molecular Mechanics (i.e., Force
Field). As a result, the QM/MM method allows a limited portion of the system to be treated with QM
accuracy, while still accounting for the rest of the protein and its environment (water solvent, biological
membrane, ions) at the atomic-level of detail. When the partition between the QM and the MM region
cuts chemical bonds, the QM subsystem is often saturated by using a hydrogen link atom [32,33].
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Typically for CYP450s the QM region is treated at fist principle level by using Density Functional
Theory (DFT), since this accounts for correlation effects at a reasonable level of accuracy. These are, in
fact, of remarkable importance for the correct description of the transition metal moiety. The accuracy
of DFT is, however, hampered by the approximated form of the exchange correlation (XC) functional.
Some of the well-known deficiencies of the commonly employed XC functionals include the neglection
of dispersion interactions, which critically affects the interactions between, e.g., aliphatic or aromatic
fragments, and the so-called self-interaction error, which may determine an unphysical electron
delocalization in open shell systems [32,34]. Modern XC functionals include empirical correction
terms to improve the description of van der Waals complexes, while a more accurate description
of radical systems can be achieved by including a fraction of exact (Hartree–Fock) exchange in the
XC functional. However, in problematic cases, specific corrections have to be introduced in order
to correct the self-interaction error [32]. The inaccuracy of the XC functional certainly affects the
chemistry of CYP450s in which the iron atom alternates among distinct possible oxidation states,
which may correspond to open or closed shell configurations and for which distinct ground spin
states may become accessible along the catalytic reaction. The coupling between the QM and the
MM layers represents the most challenging part of every mixed quantum classical method. While
van der Waals interactions, stretching, bending, and torsional terms between QM and MM regions
are accounted for by the MM terms, the electrostatic coupling is difficult, and is the bottleneck of
the QM/MM calculation. However, this is probably the most important contribution to the mixed
QM/MM Hamiltonian, as long-range electrostatic interactions can markedly affect the electronic
properties of the metal center [32,35].
QM/MM simulations can be performed by using a static or a dynamic approach. In the first
case, to study enzymatic reactions one needs to derive the dependency of the energy on the nuclear
coordinates by computing the energy for different atomic configurations via efficient algorithms, which
allow the stationary points of the potential energy surface to be located, corresponding to ground or
transition states. In the dynamical contest the system moves, instead, on a potential energy surface
which is calculated both at QM and MM level (for the two regions considered). This allows ab initio
calculations (in the QM region) to be performed at finite temperature, significantly increasing the
computational cost of the calculation with respect to classical MD. As such, the time-scale accessible
by QM/MM MD runs is limited to 100 s of ps. This clearly hampers a direct simulation of chemical
processes and enhanced sampling simulations techniques are needed to dissect possible reaction paths
and their associated free energy landscape.
3. Catalytic Mechanism of CYP450s
Considering the lack of reactivity of molecular oxygen at physiological temperatures, Nature has
supplied living systems with enzymes able to perform oxidation reactions at mild conditions. Among
these, CYP450s typically act as monooxygenase, inserting one oxygen atom into endogenous/exogenous
substrates (RH), and reducing the second oxygen to a water molecule (see Equation (1)).
NADPH + H+ + O2 + RH→ NADP+ + H2O + ROH (1)
Nowadays, it is well established that CYP450s share a general and common catalytic cycle, as
displayed in Figure 2 [36,37].
The resting state (1) of the enzyme coordinates is a water molecule in the heme distal site, which
is then displaced upon entrance of the substrate (RH) inside the binding cavity. Water departure leaves
a pentacoordinated ferric-porphyrin complex (2), which undergoes the first electron transfer (ET)
from the redox partner, leading to the formation of a high spin ferrous complex (3). This species can
easily bind molecular oxygen, forming an oxy-ferrous complex (4). After a second ET, a ferric peroxo
complex (5) is formed, which, being a strong base, can be easily protonated to form compound 0 (Cpd 0,
6). A second proton transfer induces the formation of the highly reactive iron-oxo species compound
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I (Cpd I), a FeIV-oxo porphyrin radical cation (7). In the prototypical CYP450 monooxygenase cycle,
Cpd I performs substrate hydroxylation via an oxygen rebound mechanism (8) to form an alcohol,
ROH, restoring ultimately the heme resting state (1). Whereas the protons necessary for the reactions
are supplied either from the substrate or from water molecules trapped into the binding site, the
two electrons, required at each cycle, are furnished by a specific redox partner, which by floating on
biological membrane can associate/dissociate to/from their partner proteins (among which CYP450s)
in a highly dynamic and competitive scenario.
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d = doublet, q = quartet, qu = quintet and sx = sextet) are summarized according to ref [36].
3.1. The Oxygen Rebound Mechanism
The prototypical reaction carried out by CYP450s is the C–H hydroxylation, for which the generally
accepted catalytic mechanism [6] begins with the abstraction by Cpd I of a substrate’s hydrogen atom.
This leads to a radical intermediate and a Cpd II-like iron species, beari g a hydroxyl radical. Then,
the substrate and the hy roxyl ra ical join forming the hydroxylated product (Figure 3).
Remarkably, this mechanism can also be invoked to explain other reaction types, such as esaturation,
epoxidation, heteroatom oxygenation, and dealkylation reactions [38]. Due to its importance in exogenous
and endogenous compounds metabolism, CYP450-catalyzed C–H hydroxylation has been the object of
intense experimental and computational interest, as discussed in many comprehensive reviews [8,36].
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3.2. Other Reaction Mechanisms
Although it is well established that the reactive species for most of the CYP450 oxidations is the
radical cation complex, Cpd I, an alternative mechanism, involving the ferric peroxo complex, FeO2−,
has been at times proposed to account for atypical reactions, such as the breaking of a C–C bond
(Figure S1) [39]. Furthermore, in order to rationalize some of these unusual chemical reactions, a dual
hydrogen abstraction (DHA) mechanism, relying on two subsequent hydrogen abstraction steps, has
been put forward [40,41]. In this case, a first C–H abstraction is followed by a second H-abstraction
from the hydroxyl group of the radical intermediate, leading to the aldehyde formation. A reversed
order of events, called reversed-DHA (Figure S2) may also take place.
In the following, we limit our description to reactions invoked to explain steroid biosynthesis, for
more detailed and comprehensive description on other possible reaction mechanisms promoted by all
CYP450s the reader is invited to refer to more specialized and comprehensive reviews [8,39,42].
3.3. Reaction Mechanisms of Steroidogenic CYP450s
Among the CYP450s involved in steroidogenesis only two possess exclusively a monooxygenase
function. The first, CYP21A2 (steroid 21-hydroxylase), catalyzes the 21-hydroxylation of progesterone
and 17α-hydroxyprogesterone to deoxycorticosterone and 11-deoxycortisol, respectively. The second,
CYP11B1 (steroid 11β-hydroxylase), performs the subsequent oxidation to obtain corticosterone
and cortisol, respectively. Corticosterone is later converted to aldosterone, the most potent human
mineralocorticoid, by CYP11B2 (aldosterone synthase) via a three-step catalysis. The first two, 11β-
and 18-hydroxylations are canonical monooxygenase reactions. The last step, leading to 18-oxidation,
may be rationalized with an oxygen rebound mechanism. In this chapter, we focus on the remaining
steroidogenic CYP450s, which are typified by intricate catalytic mechanisms, in which multiple
functions are merged within the same catalytic scaffold. These include: (i) CYP11A1, commonly
called cholesterol side-chain cleavage enzyme (P450scc), which catalyzes the very first step of steroid
biosynthesis; (ii) CYP17A1, which joins a 17α-hydroxylase with 17,20-lyase function catalyzing
androgens production, and (iii) CYP19A1 (commonly called Aromatase, AR), which is the only
enzyme in vertebrates able to catalyze the formation of a six-membered aromatic ring such as in
estrone or estradiol [4].
3.3.1. CYP11A1—Cholesterol Sid -Chain Cleavage Enzyme (P450scc)
In humans CYP11A1 catalyzes the synthesis of pregnenolone, the precursor of all steroid hormones
in the mitochondria. This is the first, and rate limiting step in the synthesis of all steroid hormones,
thus quantitatively regulating steroid production, and qualitatively determining the type of hormones
produced by the downstream enzymes. Pregnenolone, is synthesized in the inner membrane of
mitochondria by a complex enzymatic machinery comprising CYP11A1 and its redox partners.
CYP11A1 deficiency has been associated with lipoid congenital adrenal hyperplasia, affecting the
development of sex characteristics, while its overexpression impairs the placentation process and
contributes to the pathogenesis of pre-eclampsia [43]. Pregnenolone biosynthesis occurs in three steps
(Figure 4a). The first two are stereospecific hydroxylations leading, respectively, to the formation of
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22R-hydroxycholesterol and 20R,22R-dihydroxycholesterol, followed by the oxidative scission of the
C20–22 bond to obtain pregnenolone and isocaproic aldehyde [44].
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mechanism for the last catalytic step [45].
In line with other steroidogenic CYP450s, CP11A1 is characterized by a high substrate-specificity
limited to cholesterol, 7-dehydrocolesterol and vitamin D [46]. Cryoreduction in combination with
EPR spectroscopy showed that the reactive species responsible for the first catalytic step is Cpd I,
pinpointing a canonical hydroxylation reaction mediated by oxygen rebound [47]. By analogy, it is
probable to assume that the same mechanism may also be operative in the second step leading to the
formation of 20R,22R-dihydroxycholesterol. Despite the third step having been studied for decades, a
clear mechanistic picture remains elusive [48–50]. A C20-peroxy intermediate was invoked for the C–C
bond cleavage step (Figure 4b) on the basis of experiments showing the retention of the C22 hydrogen
and C20 oxygen in the products [48,50]. Considering the crystal structure [45] and a recent EPR study,
Cpd I was declared as the active species of the second and third catalytic steps [51]. Yet, in spite of its
pivotal importance as critical regulator of all human steroids production, a theoretical study of this
important reaction mechanism has never been attempted so far.
3.3.2. CYP17A1—Steroid 17α-Hydroxylase/17,20 Lyase (CYP450c17)
CYP17A1 is a microsomal cytochrome promoting the biosynthesis of androgens or precursor of
glucocorticoids, hence representing a critical cross point of steroid metabolism [4]. This enzyme is
a dual-function monooxygenase, exhibiting both 17-hydroxylase and 17,20 lyase functions, playing
a vital role in both adrenal and gonadal steroidogenesis. CYP17A1 converts pregnenolone and
progesterone to their 17α-hydroxylated products, and, subsequently, to dehydroepiandrosterone and
androstenedione (Figure 5a). Since prostate cancer cells proliferate in response to androgens, CYP17A1
is an important target to fight against this type of hormone-dependent cancer [52].
The 17-hydroxylation of pregnenolone and progesterone occurs via a canonical oxygen rebound
mechanism. Nevertheless, the lyase step remains object of controversy. This reaction may be either
mediated by Cpd I [53] or by the nucleophilic attack of FeO2− on the steroid C20 atom [54–56].
Recent solvent isotope effect experiments confirmed that the ferric peroxo intermediate is most likely
operative [54] (Figure 5b). Consistently, a DFT-based study, complemented by classical MD simulations,
has characterized the reaction mechanism of both the hydroxylase and lyase reactions, using Cpd I and
peroxo anion as reactive species of the two steps, respectively. For the hydroxylase step the reaction
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was studied starting from different binding poses of the substrate, as obtained from classical MD
simulations. For all these poses, similar reaction free energy barriers of 13–14 kcal/mol were obtained.
In contrast, for the lyase step two distinct mechanisms (stepwise or concerted) were discovered both
having an activation free energy of 20 kcal/mol [57]. Future studies accounting explicitly for the
influence of the biological environment and finite temperature effects may further elucidate this
catalytic mechanism, aiding the development of inhibitors which should exclusively hamper its lyase
activity to fight prostate cancer.
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3.3.3. CYP19A1—Aromatase
CYP19A1, also called Aromatase (AR), is another key player in the steroid hormone biosynthetic
pathway. This performs the conversion of androgens (androstenedione or testosterone), into estrogens
(estrone or estradiol) in a three-step reaction (Figure 6a) occurring at the inner side of the ER membrane [58].
Considering that abnormal estrogen production stimulates the proliferation of estrogen dependent
breast cancer, this enzyme represents a key pharmacological target against this disease. For this
reason, AR has been the object of several studies aimed at tackling distinct aspects of its reaction
mechanism [59,60] and searching for novel competitive inhibitors [58,61,62]. As for the other
steroidogenic CYP450s, AR catalysis has been the object of debate and initially believed to be different
from the canonical CYP450s due to the highly hydrophobic nature and substrate specificity of the
active site. Nowadays, it is well established that the first two hydroxylation steps are mediated by Cpd
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I, involving a canonical hydrogen abstraction and hydroxyl radical rebound mechanism (Figure 3).
After the two hydroxylation steps a 19,19-gem-diol (gem-diol, Figure 6a) is formed. Several reaction
mechanisms have been proposed for the last catalytic step in which the aromatization of the substrate
A ring takes place: among these, the Baeyer–Villiger oxidation of C19 [63], 4,5 epoxidation [64],
and 2β hydroxylation [65,66]. On the basis of 18O labelling experiments [63,67,68], the commonly
accepted mechanism relied on the nucleophilic attack of the ferric peroxo complex, FeO2−, to the
aldehyde group of a dehydrated gem-diol, with estrone being formed by the decomposition of a
peroxo hemiacetal (Figure 6b). Pure QM and QM/MM studies, based on DFT, identified distinct
mechanisms in which the peroxo ferric intermediate was operative overcoming free energy barriers
in line with experiments [8,36]. Yet none of these studies provided a clear comprehensive picture
of the whole catalytic cycle. Conversely, recent experimental studies, based on resonance Raman
spectroscopy [69], Kinetic Solvent Isotope Effect [70], and new 18O labelling studies [71] definitively
pinpointed Cpd I as the reactive species of the last step. In a recent work, by performing a sophisticated
computational protocol relying on extensive FF-based and QM/MM metadynamics simulations, a
comprehensive atomic-level picture of AR catalysis was provided (Figure 7), disclosing that, after the
first two hydroxylation steps, in which also a 2,3-enol formation takes place, a non-canonical DHA
mechanism completes substrate aromatization (Figure 6c) [41,72].
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4. CYP450s’ Choreography on the Biological Membranes’ Surface
Human CYP450s are attached via an N-terminal anchor to the ER and mitochondrial membranes.
These play an active role in regulating the function of CYP450s. As an example, membranes (i) affect
partitioning and accumulation of hydrophobic substrates [73], which should travel into the buried
CYP450s active site facing the membrane (Figure 8), (ii) influence the structural and dynamical traits,
such as the penetration and orientation of CYP450 with respect to the lipidic bilayer plane, inducing a
fine tuning of the proteins slow functional motions underlining the opening and closing of substrate
egress/access channels, (iii) condition the CYP450s’ ability to dynamically diffuse on the top of the
membrane in search of its redox or other protein partners involved in catalysis as well as in its
post-transcriptional regulation [74,75]. Despite their critical impact on CYP450 function, membranes
have only recently been considered in computational studies [16,17].
MD simulations, in agreement with experimental studies, provided an atomic-level structural
model of many CYP450s embedded in distinct membrane types, consistently showing that the proteins
extend above the membrane surface, while remaining anchored via its N-terminal helix. Conversely
the proximal side, above the heme moiety, remains exposed towards the solvent in order to establish
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interactions with the CYP450 specific redox partner. CYP450s are partly immersed in the hydrophobic
framework of the membrane (with the F/G-loop being deeply buried in the bilayer, while the B/C-loop
and β1, β2, β4–β5 sheets interact with it) and assume a characteristic heme tilt angle (the tilt angle
accounts for the orientation of the heme moiety with respect to the membrane plane) oscillating
between 30–89 degrees [2]. These interactions and, in turn, CYP450s’ orientation are also remarkably
affected by the membrane composition [2,75].Catalysts 2018, 8, x FOR PEER REVIEW  12 of 22 
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Access Channels
CYP450s are characterized by buried active sites connected to the protein surface via multiple
arduous channels [76]. Identifying and characterizing the size and shape of those channels, as well as
the structural and dynamic traits of ligands (substrate and inhibitors) channeling through them, to
reach the catalytic site, is of pivotal importance from either a fundamental biochemical understanding
or a pharmaceutical point of view [19]. These properties may indeed affect CYP450s ligand selectivity
(kcat/km) and drug efficacy (residence time of a drug at the target site). In spite of its importance,
unraveling ligand channeling energetics remains a daunting challenge to be addressed by experimental
techniques, since the free energy landscape is most likely characterized by multiple metastable states. In
this respect, computational methods can shed light on this biological process and several computational
tools have been developed to this end (i.e., CAVER [77], MOLE [78] and MOLEonline [79]). Moreover,
recently even a database of all known CYP450 channels, called ChannelDB, has been released [80].
CYP19A1 and CYP17A1 on the ER Membrane
Among steroidogenic CYP450s, this issue has been faced for AR attached to a 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) membrane [17]. A first study of this enzyme, immersed in water
solution and in the membrane mimic, revealed an increased flexibility of the protein residues in contact
with the membrane in comparison to the simulation performed in water. Moreover, RAMD simulations
revealed that the membrane markedly affected the type and the number of viable channels [81].
A different work investigated also the influence of distinct membrane compositions on CYP19A1,
obtaining analogous results [82]. Similarly, an MD simulation study supplied a structural model
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of the binding of CYP17A1, and, consistently with other CYP450s, disclosed a significant impact
of the membrane interface on the structure and dynamics and on the opening/closing of different
tunnels [83]. Nevertheless, to understand the viability of those channels by substrates/inhibitors
their ranking according to cost of ligands passage is required [84]. This can be achieved only by
computing the relative free energy profile of ligand channeling by enhanced sampling simulations. In
a recent study [21], AR channels were mapped using multiple SMD simulations, which allowed only
the relative probability of travelling along them to be assessed, while the profiles were computed by
US simulations. Strikingly, as a result, ligands differing in terms of size, hydrophobicity, shape (the
substrate androstenedione and a potent clinically used inhibitor letrozole), preferentially travel along
the same channels (Figure 8) to get into or dissociate from the active site. A bioinformatics analysis
revealed that these preferential paths may be even conserved among distinct CYP450s.
5. Interaction with Specific Redox Partners
The biotransformation processes catalyzed by all mammalian CYP450s depend on their redox
partners, which supply the electrons necessary for catalysis (two electrons are needed for each
mono-oxygenation reaction) [85]. In the microsomal electron transport chain, CPR and CYb5 are
the main electron donors for those CYP450s anchored to the ER membrane [86]. Conversely, at the
mitochondrial membrane the electrons are donated by the ferredoxin redox system (adrenodoxin
reductase (AdR) or adrenodoxin (Adx)) [45].
5.1. NADPH-Cythochrome P450 Reductase (CPR)
CPR is a membrane-bound protein composed of three domains separated by a linker domain and
a flexible hinge, each binding a cofactor crucial for its function. These cofactors are the nicotinamide
adenine dinucleotide phosphate (NADPH), the flavin adenine dinucleotide (FAD) and the flavin
mononucleotide (FMN) [87,88]. CPR promotes the electron transfer (ET) from NADPH to CYP450s
with CYP:CPR ratio of 3–15:1. However, CPR also supplies electrons to many other proteins besides
CYP450s, in a highly competitive scenario [89].
Experimental studies revealed that CPR exists in equilibrium between two conformational (closed
and open) states [90] and that the balance between the two conformations depends on the redox state
of the NADPH cofactor. In this scenario, the open conformation serves to facilitate ET within the CPR
in two steps: (i) two electrons, are consecutively transferred from NADPH to FAD and, (ii) then they
move from FAD to the FMN group. In the open conformation, the FMN cofactor is exposed to the
solvent, thus, upon diffusing on the ER membrane, CPR can recruit its target protein, inducing the
ET from FMN domain to the heme iron. During the transition from a closed to open conformation
NADPH and FAD domains change their position, moving significantly away from the membrane
surface, while the FMN remains in its proximity, with the FMN cofactor being solvent exposed [91].
This is a necessary prerequisite for the successful interaction with CYP450s.
The importance of the interaction between CYP450s and their CPR redox partner for catalysis
may even go beyond the mere supplement of electrons. Recent MD simulations complemented by
QM/MM of the CYP450 BM3 in complex with FMN domain, with and without the substrate bound
in the CYP450 active site, elucidated that the FMN domain must undergo significant conformational
changes to approach the heme moiety, accelerating in this manner the ET [92]. This study revealed
that the interaction between the α1-helix of CPR and the C-helix of the heme of CYP450 BM3 was
enhanced by a reorientation of this helix to a thermochemically stable form gated and choreographed
by substrate binding [92]. It is, however, unclear if this ligand-induced allosteric enhancement of ET
may be operative even in steroidogenic enzymes, whose high substrate specificity is often intertwined
with active site rigidity.
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CPR/CYP19A1 Adduct
Because of its intricacy and the lack of structural information on the CPR/CYP450s adduct,
the mechanism of ET and its modulation by the membrane environment remains elusive. The only
structure of a CPR/CYP450 adduct was solved for the heme and FMN-binding domain of bacterial
P450 (PDB: IBVY) reported by Sevrioukova et al. [93]. The structure was used as a starting point to
build and relax, via a 7 ns-long MD simulation, the adduct between CPR and CYP19A1. This, along
with other studies, revealed that the interaction between CPR and CYP450 is essentially based on
electrostatic interactions [94] and suggested that ET may be here mediated by water molecules lying
at the interface of the two proteins [95]. Distinct studies showed that the FMN domain of the CPR is
rich in acidic amino acids, while that of AR is positively charged by lysine and arginine residues at
the proximal site where CPR binds [85]. This was confirmed by mutagenesis experiments showing
that upon mutations of key Lys residues, such as Lys108, AR loses its catalytic activity. Similarly, a
study done by us on either the FMN domain/AR adduct or the complete CPR/AR model (Figure 9),
both embedded in a membrane mimic, carried out by consensus protein docking studies (i.e., use of
distinct docking programs based on different scoring functions and search methods) resulted in only
one stable binding pose stabilized by electrostatic interaction [96].
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5.2. Cythochrome b5 (CYb5) 
CYb5 is a heme protein bound to the ER, which actively participates in many reactions mediated 
by CYP450s, providing the electrons necessary for their catalysis [97]. According to experimental 
data, CYb5 can be reduced by accepting electrons from the NADH-cytochrome b5 reductase (CYbR), 
or from CPR (Figure 10a), acting therefore as an electron shuttle. After the reduction, CYb5 is able to 
modulate CYP450 catalysis [86]. 
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5.2. Cythochrome b5 (CYb5)
CYb5 is a heme protein bound to the ER, which actively participates in many reactions mediated
by CYP450s, providing the electrons necessary for their catalysis [97]. According to experimental data,
CYb5 can be reduced by accepting electrons from the NADH-cytochrome b5 reductase (CYbR), or
from CPR (Figure 10a), acting therefore as an electron shuttle. After the reduction, CYb5 is able to
modulate CYP450 catalysis [86].
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CYPb5 can reduce many CYP450s, among which the oxy-ferrous form of CYP17A1, is 10-fold
faster than the CPR. As detailed above, CYP17A1 catalyzes the synthesis of androgens from the
steroid precursors, pregnenolone and progesterone, in two steps: allylic hydroxylation and lyase
reaction. CYb5 has been suggested to promote the latter reaction, transferring only one electron due
to its low redox potential (+20 mV) [2]. Therefore, considering the CYP450 catalytic cycle (Figure 2),
CYb5 intervenes after the formation of the oxy-ferrous complex (4), providing the second electron
to complete the reduction cycle. At this point, the lyase reaction of 17-hydroxy-pregnenolone, as
well as 17-hydroxy-progesterone, proceeds through a nucleophilic attack on the carbonyl group of
the substrate, forming a peroxo-hemiketal intermediate. This can undergo homolytic or heterolytic
cleavage of the O–O bond and rearrange to release the dehydroepiandrosterone product and a molecule
of acetic acid [98,99].
5.3. Adrenodoxin (Adx)
Adx is [2Fe-2S] ferredoxin, which, on receiving electrons from a FAD-containing Adx reductase
(AdR), transfers them to mitochondrial CYP450s (Figure 10b). The electrons are supplied to AdR by
NADPH. The molecular mechanism of complex formation and electron transport within this system
has remained unclear: AdR, Adx, and CYP450 have been proposed to form 1:1:1 or 1:2:1 complexes,
but Adx has also been suggested to act as a shuttle, sequentially transporting one electron at a time
from AdR to CYP450. In both the complex and shuttle models the interactions between the protein
pairs are mainly electrostatically driven. Brownian dynamics simulations attempted to characterize
the Adx/CYP11A1 adduct, confirming this hypothesis [94].
6. Post-Transcriptional Regulation of CYP450s Activity
Kinase enzymes promote wide spread regulatory mechanisms by phosphorylating their target
proteins, and inducing, as a result, their activation/inactivation and/or functional changes. Among
their possible targets, also CYP450s can be post-transcriptional regulated by kinases [99].
6.1. CYP19A1 Phosphoryl tion
Phosphorylation of AR acts as functional switch mechanism for estrogen modulation. It has been
shown that phosphorylation by insulin-like growth factor-1 increases AR activity in breast cancer
cells [100]. Additionally, it was reported that exposure of estrogen-dependent MCF-7 and ZR75 BC
cells to estrogens (i.e., 17β-estradiol) increases the phosphorylation status, and, in turn, the activity
of AR. Phosphorylation occurs at Tyr361 and it is induced by c-Src kinase [101,102]. Additionally,
exposure of estrogen receptor positive breast cancer cells to estrogens even inhibits the phosphatase
PTP1B ability to de-phosphorylate AR. Hence, estrogens perform a dual function convergently leading
their enhanced biosynthesis via AR activation by phosphorylation, and, simultaneous inhibition of
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PTP1B [102]. As a result, estrogens, synthesized by AR, bind the estrogen receptor α, and send signals
to c-Src. These signals promote the phosphorylation of Tyr361, which increases AR activity leading
to an augmented local estrogen production with possible implications in breast cancer onset and
progression. Tyr361 lies in the heme proximal cavity of AR, and, since its mutation to Phe dramatically
decreases AR activity, it is likely involved in the ET from CPR to AR. Despite mounting evidences
on phosphorylation of AR in multiple tissues, the mechanism underlying this post-transcriptional
regulation of estrogen biosynthesis remains poorly understood. Recent computational studies
highlighted how the phosphorylation of Tyr361 enhances the stabilization of the AR/CPR adduct,
facilitating AR in the competition with other CYP450s for the CPR [96].
6.2. CYP17A1 Phosphorylation
Human CYP17A1 is phosphorylated on serine and threonine residues by Protein Kinase A (PKA).
Phosphorylation increases enzyme activity, affecting exclusively the lyase reaction, while having
no effect on allylic hydroxylation [103]. As for AR, dephosphorylation has an opposite regulatory
effect [104]. Mutagenesis studies pinpointed Ser427 and Thr341 as possible phosphorylation sites [105].
Despite its importance, how phosphorylation affects the mechanism of this enzyme remains elusive
and has never been addressed at computational level.
6.3. CYP11A1 Phosphorylation
Remarkably, even the synthesis of pregnenolone at inner mitochondrial membrane by CYP11A1 is
regulated by phosphorylation. Experimental data indicate that PKA can phosphorylate CYP11A1 serine
and threonine amino acids, enhancing as a result their enzymatic activity [106]. In addition, CYP11A1
is actively and selectively phosphorylated by the phospholipid and calcium dependent protein kinase
C (PKC) in vitro [107]. In mitochondria, the electrons necessary for cholesterol metabolism biosynthesis
are shuttled to CYP11A1 by Adx. A combined experimental and computational study relying on
stopped-flow experiments and Brownian dynamics has addressed this steroid hydroxylating system from
bovine adrenal glands. Despite this study being focused on the phosphorylation of Adx at Thr71 by
casein kinase 2 (CK2), it disclosed that upon phosphorylation the binding affinity of Adx towards
CYP11A1 increases, consistently with the findings illustrated above. The Adx/CYP450 complex adopts
a geometry able to increase the ET rate with respect to the wild type counterpart. These findings,
evidence the existence of a general mechanism of post-transcriptional regulation in CYP450s, which
remains to be investigated in more detail.
7. Conclusions and Perspectives
Understanding the mechanism of steroidogenesis at atomic level is of pivotal importance in
disclosing the fundamental biological principles leading to sexual differentiation, reproduction, and
fertility; to dissect the multiple finely tuned regulatory mechanisms controlling these pathways
and to exploit this information for therapeutic intervention against disorders caused by steroid
deregulation [4].
In recent years, a growing body of experimental and theoretical studies have contributed
to unravel controversial steps of the complex catalytic mechanisms of steroidogenic
CYP450s [41,45,47,59,71,108]. Nonetheless, a comprehensive theoretical investigation of CYP17A1 and
CYP11A1 catalytic mechanism is still missing in order to further confirm the functional classification
of these enzymes. Instead, computational studies have remarkably contributed in disclosing the
central role of membranes in the CYP450s functions. A consensus general structural model of CYP450s
on the membrane surface has now been reached, as well as the establishment of the crucial role of
membranes in affecting channel opening. Conversely, how membranes modulate the traveling of
distinct substrate/inhibitor through protein channels has only lately started to be tackled. Furthermore,
several aspects remain to be investigated, such as the role of the membrane in fine tuning the CYP450s
redox potential [11].
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Being membranes vital for CYP450s, a detailed atomic-level picture of the association/dissociation
and competition with the distinct protein partners occurring at the membrane interface is also of utmost
importance. Current research efforts are devoted to unravel how protein–protein interactions modulate
CYP450s catalysis [19]. These mainly involve the interactions of CYP450s with their reducing partners
as well as even more complex structures formed by CYP450s’ dimers or polymers [19].
Of relevance is the so far largely unexplored mechanism of post-translational regulation of CYP450
catalysis, by phosphorylation/de-phosphorylation. Distinct studies converge to a scenario in which
by altering the electrostatic potential of the CYP450 (or its redox partner) the resulting adduct gains
stability by establishing stronger electrostatic interactions. This may increase either the redox potential
of the process or simply limit the competition among the phosphorylated CYP450s and the other
proteins contending for the same redox partner. Understanding the fascinating regulatory process
of steroidogenesis has also potential implications for developing knowledge-based small-molecule
regulators able to damp/control CYP450 catalysis enhancement with the aim of counteracting cancer
diseases (mainly prostate and breast).
We expect that atomic-level understanding of the intricate molecular framework underlining
steroidogenic CYP450s’ function in their native environment [2] will be significantly expanded in
forthcoming years, allowing further steps to be taken towards the clinical management of diseases
associated with steroidogenic disorders [108].
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